Yu-Sheng Chang, M.D., from Shuang Ho Hospital in Taipei, Taiwan, and colleagues conducted a nationwide, population-based study to assess the risk of SAH among patients with SLE. The incidence of SAH was compared in a cohort of 16,967 patients with SLE identified from the Taiwan National Health Insurance (NHI) database and 16,967 randomly selected age- and sex-matched individuals without SLE.
The researchers found that the incidence of SAH was significantly higher in the SLE cohort (incidence rate ratio, 4.84). Compared with all the non-SLE SAH patients identified from the NHI database, the mortality rate after SAH was significantly higher for patients with SLE, despite a younger age (60 versus 38.9 percent). Independent risk factors for new-onset SAH included age (hazard ratio [HR], 1.03); platelet transfusion (HR, 2.75); red blood cell transfusion (HR, 7.11); and a mean daily steroid dose greater than 10 mg prednisolone or equivalent (HR, 4.36).
“In conclusion, our study is the first to demonstrate a higher risk of SAH in SLE patients using a nationwide population data set,†the authors write. “Elderly SLE patients and those with a higher mean daily steroid dose and a history of platelet or red blood cell transfusion had a higher risk of developing SAH.â€
More information: Abstract
Full Text (subscription or payment may be required)
Journal reference:
Arthritis Care Research
Health News Copyright © 2013 HealthDay. All rights reserved.
<!–
>
-
-
- 0
-
-
-
-
to facebook
- FB
-
- Tweet
-
Reddit
Google
Delicious
Slashdot
Yahoo! bookmarks
RSS
QR code
<!–
>